High Affinity Nerve Growth Factor Receptor - Pipeline Review, H2 2017

  • ID: 4426893
  • Report
  • 102 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Array BioPharma Inc
  • AstraZeneca Plc
  • Dompe Farmaceutici SpA
  • Handok Inc
  • Loxo Oncology Inc
  • Plexxikon Inc
  • MORE
High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Pipeline Review, H2 2017

Summary

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Tropomyosin receptor kinase A or high affinity nerve growth factor receptor is a protein encoded by the NTRK1 gene. High affinity receptor for NGF bind and be activated by NTF3/neurotrophin-3. Upon dimeric NGF ligand-binding undergoes homodimerization, autophosphorylation and activation. It phosphorylates and/or activates several downstream effectors including SHC1, FRS2, SH2B1, SH2B2 and PLCG1 that regulate distinct overlapping signaling cascades driving cell survival and differentiation.

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 7 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Immunology, Dermatology, Metabolic Disorders and Ophthalmology which include indications Alzheimer's Disease, Osteoarthritis Pain, Solid Tumor, Breast Cancer, Colorectal Cancer, Fibrosarcoma, Non-Small Cell Lung Cancer, Amyotrophic Lateral Sclerosis, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Central Nervous System (CNS) Tumor, Inflammatory Pain, Melanoma, Neuroblastoma, Neuroendocrine Tumors, Ovarian Cancer, Pain, Pancreatic Cancer, Papillary Thyroid Cancer, Pruritus, Salivary Gland Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Large Cell Lymphoma (ALCL), Astrocytoma, Atopic Dermatitis, Biliary Tumor, Chronic Pain, Colon Cancer, Diabetic Retinopathy, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Inflammation, Keratoconjunctivitis sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Low Back Pain, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Multiple Sclerosis, Neuropathic Pain, Non-Small Cell Lung Carcinoma, Open-Angle Glaucoma, Plaque Psoriasis (Psoriasis Vulgaris), Pontine Glioma, Prostate Cancer, Psoriasis, Renal Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Soft Tissue Sarcoma, Tenosynovial Giant Cell Tumor, Thymic Carcinoma and Thyroid Cancer.

The latest report High Affinity Nerve Growth Factor Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • The report reviews High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Array BioPharma Inc
  • AstraZeneca Plc
  • Dompe Farmaceutici SpA
  • Handok Inc
  • Loxo Oncology Inc
  • Plexxikon Inc
  • MORE
Introduction

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Overview

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development

Array BioPharma Inc

Astellas Pharma Inc

AstraZeneca Plc

Daiichi Sankyo Co Ltd

Dompe Farmaceutici SpA

Genzyme Corp

Handok Inc

Ignyta Inc

Loxo Oncology Inc

Merck & Co Inc

Nerviano Medical Sciences Srl

Plexxikon Inc

Proximagen Ltd

Rottapharm Biotech Srl

Sienna Biopharmaceuticals Inc

Tiziana Life Sciences Plc

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Drug Profiles

ACD-855 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AR-523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-954 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-7962 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-7451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNN-27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenegermin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRB-0089 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-6051 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-389988 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

larotrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit TrkA for Central Nervous System Disorders and Peripheral Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-626 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOV-1601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TrkA for Inflammatory Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize TrkA and TrkB for Alzheimer’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TRK1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Dormant Products

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Discontinued Products

High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120

Oct 19, 2017: AlzeCure to Present Data on NeuroRestore Project at 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD)

Oct 18, 2017: Loxo Oncology Announces Positive Top-Line Results from Independent Review Committee Assessment of Larotrectinib Dataset

Oct 17, 2017: Ignyta Receives European Medicines Agency Prime Designation for Entrectinib in NTRK Fusion-Positive Solid Tumors

Oct 17, 2017: Interim Analysis of Ignytas Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer

Oct 17, 2017: Promising Phase 1/2 Results for Entrectinib Against ROS1+ Non-Small Cell Lung Cancer

Sep 27, 2017: Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer

Sep 11, 2017: Ignyta to Provide Update on Entrectinib at ESMO 2017 Congress

Sep 07, 2017: Ignyta To Host Conference Call And Live Webcast On September 11 To Provide Pipeline Review, Including Lead Candidate Entrectinib

Sep 06, 2017: Ignyta Provides Regulatory Update on Entrectinib ROS1 Lung Cancer Development Program

Aug 31, 2017: Daiichi Sankyo to Present Data on Tumor Drug Candidate DS-6051 at the European Society for Medical Oncology 2017 Congress

Aug 30, 2017: Ignyta to Host Conference Call and Webcast on Entrectinib ROS1 Lung Cancer Update on September 6, 2017

Jul 20, 2017: Cenegermin Eye Drops Receive European Union Approval: The First Biotechnological Drug Resulting from Dompe Research for the Treatment of Moderate to Severe Neurotrophic Keratitis is Made in Italy

Jul 19, 2017: Tiziana Life Sciences Announces Initiation of a Phase IIa Clinical Trial with Milciclib in Patients with Hepatocellular Carcinoma

Jul 10, 2017: Dompe Farmaceutici Receives EU marketing authorisation For OXERVATE

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Array BioPharma Inc, H2 2017

Pipeline by Astellas Pharma Inc, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by Daiichi Sankyo Co Ltd, H2 2017

Pipeline by Dompe Farmaceutici SpA, H2 2017

Pipeline by Genzyme Corp, H2 2017

Pipeline by Handok Inc, H2 2017

Pipeline by Ignyta Inc, H2 2017

Pipeline by Loxo Oncology Inc, H2 2017

Pipeline by Merck & Co Inc, H2 2017

Pipeline by Nerviano Medical Sciences Srl, H2 2017

Pipeline by Plexxikon Inc, H2 2017

Pipeline by Proximagen Ltd, H2 2017

Pipeline by Rottapharm Biotech Srl, H2 2017

Pipeline by Sienna Biopharmaceuticals Inc, H2 2017

Pipeline by Tiziana Life Sciences Plc, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Array BioPharma Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Daiichi Sankyo Co Ltd
  • Dompe Farmaceutici SpA
  • Genzyme Corp
  • Handok Inc
  • Ignyta Inc
  • Loxo Oncology Inc
  • Merck & Co Inc
  • Nerviano Medical Sciences Srl
  • Plexxikon Inc
  • Proximagen Ltd
  • Rottapharm Biotech Srl
  • Sienna Biopharmaceuticals Inc
  • Tiziana Life Sciences Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll